Abstract
Our objective, in this evidence-based chapter on stroke, is to present epidemiological, diagnostic, treatment, and prognostic factors for several selected topics in the clinical areas of transient ischemic attack, cardioembolic stroke, acute ischemic stroke, lacunar stroke, and carotid stenosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Johnston SC. Clinical practice. Transient ischemic attack. N Engl J Med. 2002;347:1687–92.
Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276–93.
Levy DE. How transient are transient ischemic attacks? Neurology. 1988;38:674–7.
Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. New Engl J Med. 1977;296:358–62.
Weisberg LA. Clinical characteristics of transient ischemic attacks in black patients. Neurology. 1991;41:1410–4.
Bots ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient neurological attacks in the general population. Prevalence, risk factors, and clinical relevance. Stroke. 1997;28:768–73.
Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006;60:301–13.
Furst G, Saleh A, Wenserski F, et al. Reliability and validity of noninvasive imaging of internal carotid artery pseudo-occlusion. Stroke. 1999;30:1444–9.
Forsting M, Wanke I. Funeral for a friend [comment]. Stroke. 2003;34:1324–32.
Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. Stroke. 2003;34:1324–32.
Josephson SA, Bryant SO, Mak HK, Johnston SC, Dillon WP, Smith WS. Evaluation of carotid stenosis using CT angiography in the initial evaluation of stroke and TIA. Neurology. 2004;63:457–60.
Anderson GB, Ashforth R, Steinke DE, Ferdinandy R, Findlay JM. CT angiography for the detection and characterization of carotid artery bifurcation disease. Stroke. 2000;31:2168–74.
Silvennoinen HM, Ikonen S, Soinne L, Railo M, Valanne L. CT angiographic analysis of carotid artery stenosis: comparison of manual assessment, semiautomatic vessel analysis, and digital subtraction angiography. Am J Neuroradiol. 2007;28:97–103.
Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901–6.
Nguyen-Huynh MN, Johnston SC. Is hospitalization after TIA cost-effective on the basis of treatment with tPA? Neurology. 2005;65:1799–801.
Fallon C, Noone I, Ryan J, O’Shea D, O’Laoide R, Crowe M. Assessment and management of transient ischaemic attack–the role of the TIA clinic. Irish J Med Sci. 2006;175:24–7.
Josephson SA, Sidney S, Pham TN, Bernstein AL, Johnston SC. Higher ABCD2 score predicts patients most likely to have true transient ischemic attack. Stroke. 2008;39:3096–8.
Josephson SA, Sidney S, Pham TN, Bernstein AL, Johnston SC. Factors associated with the decision to hospitalize patients after transient ischemic attack before publication of prediction rules. Stroke. 2008;39:411–3.
Coben JH, Owens PL, Steiner CA, Crocco TJ. Hospital and demographic influences on the disposition of transient ischemic attack. Acad Emerg Med. 2008;15:171–6.
Byrne A, Daly C, Rocke L, Gray J. Can risk stratification of transient ischaemic attacks improve patient care in the emergency department? Emerg Med J. 2007;24:637–40.
Bray JE, Coughlan K, Bladin C. Can the ABCD Score be dichotomised to identify high-risk patients with transient ischaemic attack in the emergency department? Emerg Med J. 2007;24:92–5.
Nguyen-Huynh MN, Johnston SC. Transient ischemic attack: a neurologic emergency. Curr Neurol Neurosci Rep. 2005;5:13–20.
Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005;366:29–36.
Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–92.
Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665–73.
Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New Engl J Med. 2008;359:1238–51.
Kent DM, Thaler DE. Stroke prevention–insights from incoherence. New Engl J Med. 2008;359:1287–9.
Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577–617.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:630S–69.
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:546S–92.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:483S–512.
Toth C. The use of a bolus of intravenous heparin while initiating heparin therapy in anticoagulation following transient ischemic attack or stroke does not lead to increased morbidity or mortality. Blood Coagul Fibrinolysis. 2003;14:463–8.
Lengyel M, Vandor L. The role of thrombolysis in the management of left-sided prosthetic valve thrombosis: a study of 85 cases diagnosed by transesophageal echocardiography. J Heart Valve Dis. 2001;10:636–49.
Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119:108S–21.
Morgan MK, Sekhon LH, Finfer S, Grinnell V. Delayed neurological deterioration following resection of arteriovenous malformations of the brain. J Neurosurg. 1999;90:695–701.
del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4–11.
Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–30.
Asinger RW, Dyken ML, Fisher M, Hart RG, Sherman DG. Cardiogenic brain embolism: the second report of Cerebral Embolism Task Force. Arch Neurol. 1989;46:723–43.
Bogousslavsky J, Cachin C, Regli F, Despland PA, Van Melle G, Kappenberger L. Cardiac sources of embolism and cerebral infarction–clinical consequences and vascular concomitants: the Lausanne Stroke Registry. Neurology. 1991;41:855–9.
Caplan L. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture-2000. Stroke. 2000;31:2011–23.
Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. Ann Neurol. 2004;56:389–98.
Bogousslavsky J, Regli F, Maeder P, Meuli R, Nader J. The etiology of posterior circulation infarcts: a prospective study using magnetic resonance imaging and magnetic resonance angiography. Neurology. 1993;43:1528–33.
Glass TA, Hennessey PM, Pazdera L, et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry [see comment]. Arch Neurol. 2002;59:369–76.
Schonewille WJ, Wijman CA, Michel P, Algra A, Kappelle LJ. The Basilar Artery International Cooperative Study (BASICS). Int J Stroke. 2007;2:220.
Pessin MS, Lathi ES, Cohen MB, Kwan ES, Hedges 3rd TR, Caplan LR. Clinical features and mechanism of occipital infarction. Ann Neurol. 1987;21:290–9.
Yamamoto Y, Georgiadis AL, Chang HM, Caplan LR. Posterior cerebral artery territory infarcts in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 1999;56:824–32.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.
Sila CA. Cardioembolic Stroke. In: Noseworthy JH, editor. Neurological Therapeutics: Principles and Practice, vol. 1. London: Martin Dunitz; 2003. p. 450–7.
Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. New Engl J Med. 2007;357:2262–8.
Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. New Engl J Med. 2001;345:1740–6.
Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke [see comment][erratum appears in N Engl J Med. 2006 Jun 1;354(22):2401]. New Engl J Med. 2005;353:2361–72.
Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469–73.
Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131:688–95.
Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32:803–8.
Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119:194S–206.
Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20:527–32.
Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol. 1995;76:355–8.
Adams Jr HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115:e478–534.
Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol. 2007;50:187–204.
Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.[see comment][erratum appears in Lancet 2001 Oct 13;358(9289):1276]. Lancet. 2001;358:702–10.
Bruno A, Biller J, Adams Jr HP, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999;52:280–4.
Dalal PM, Mishra NK, Bhattacharjee M, Bhat P. Antithrombotic agents in cerebral ischaemia. J Assoc Physicians India. 2006;54:555–61.
Graham SP. To anticoagulate or not to anticoagulate patients with cardiomyopathy. Cardiol Clin. 2001;19:605–15.
Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39–43.
Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy [see comment]. J Am Coll Cardiol. 2003;42:1066–72.
Sandercock P. Full heparin anticoagulation should not be used in acute ischemic stroke. Stroke. 2003;34:231–2.
Teitelbaum JS, von Kummer R, Gjesdal K, et al. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. Can J Neurol Sci. 2008;35:160–5.
Yasaka M, Yamaguchi T. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. CNS Drugs. 2001;15:623–31.
Anonymous. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators [see comment]. New Engl J Med. 1990;323:1505–11.
Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830–5.
Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175–9.
Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349–55.
Anonymous. Stroke Prevention in Atrial Fibrillation Study. Final results [see comment]. Circulation 1991;84:527–39.
Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;109:45–51.
Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [erratum appears in Arch Intern Med 1994 Oct 10;154(19):2254]. Arch Intern Med. 1994;154:1449–57.
Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579S–89.
Anonymous. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators [see comment]. JAMA 1998;279:1273–7.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.
Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000;356:1648–51.
Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294:366–9.
Messe SR, Silverman IE, Kizer JR, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology [see comment]. Neurology. 2004;62:1042–50.
Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke [see comment]. New Engl J Med. 1994;331:1474–9.
Fujimoto S, Yasaka M, Otsubo R, Oe H, Nagatsuka K, Minematsu K. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke. 2004;35:1426–9.
Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque [see comment]. Am J Cardiol. 2002;90:1320–5.
Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke [see comment]. J Am Coll Cardiol. 1998;31:134–8.
Meyer BC, Raman R, Hemmen T, Obler R, Zivin JA, Rao R, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. 2008;7(9):787–95.
Capampangan DJ et al. Telemedicine versus telephone for remote emergency stroke consultations. A critically appraised topic. Neurologist. 2009;15:163–6.
Rosso C et al. Diffusion-weighted MRI in acute stroke within the first 6 hours: 1.5 or 3.0 Tesla. Neurology. 2010;74:1946–53.
Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol. 2004;61:1066–70.
Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38:2279–83.
Gadhia J et al. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke. 2010;41:300–6.
Saver JL et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window. Joint outcome table analysis of the ECASS trial. Stroke. 2009;40:2433–7.
Norrving B. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol. 2008;8:222–8.
Bejot Y, Catteau A, Caillier M, Rouaud O, Durier J, et al. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population based study. Stroke. 2008;39:1945–51.
Benavente O et al. Small vessel strokes. Curr Cardiol Rep. 2005;7:23–8.
Schonewille WJ, Tuhrim S, Singer MB, Atlas SW. Diffusion-weighted MRI in acute lacunar syndromes. A clinical-radiological correlation study. Stroke. 1999;30(10):2066–9.
Arboix A, Marti-Vilalta JL. Lacunar stroke. Expert Rev Neurother. 2009;9(2):179–96.
Benavente OR et al. and for the SPS3 Investigators. The secondary prevention of small Âsubcortical strokes (SPS3) study. International journal of stroke. 2011;6:164–75. doi: 10.1111/j.1747-4949.2010.00573.x.
Fluri F et al. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol. 2010;17:1054–60.
Jackson C et al. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain. 2005;128:2507–17.
Sacco S et al. A population based study of the incidence and prognosis of lacunar stroke. Neurology. 2006;66:1335–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Aguilar, M.I., Demaerschalk, B.M. (2012). Stroke. In: Burneo, J., Demaerschalk, B., Jenkins, M. (eds) Neurology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88555-1_4
Download citation
DOI: https://doi.org/10.1007/978-0-387-88555-1_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-88554-4
Online ISBN: 978-0-387-88555-1
eBook Packages: MedicineMedicine (R0)